How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,908 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. "GENIPSO": a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. (Abstract)

"GENIPSO": a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Genital psoriasis is often under-recognized.To assess the instantaneous prevalence of genital psoriasis and describe its clinical features, association with a particular subtype of psoriasis and its impact on general and sexual quality of life (QoL).GENIPSO is a prospective study conducted by private and hospital (...) -based dermatologists. This study featured the consecutive inclusion of patients consulting for extragenital psoriasis. The clinical features of psoriasis and genital psoriasis were recorded and QoL and sexual health questionnaires were distributed to patients.Overall, 335 of 776 patients (43·2%) included in the study had genital involvement. All were aware that they had genital lesions but only 135 patients (40%) declared that they had been previously examined. Genital lesions were associated

2018 British Journal of Dermatology

122. Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007–2016) Full Text available with Trip Pro

Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007–2016) Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the general population.To evaluate the epidemiology and clinical characteristics of patients with psoriasis who seek treatment in outpatient dermatology clinics throughout hospitals in Malaysia.Data were obtained from the Malaysian Psoriasis Registry (MPR). All patients (aged 18 (...) and above) who were notified to the registry from July 2017 to December 2017 were included in this study.Among 15,794 patients, Malays were the most common (50.4%), followed by Chinese (21.4%), Indian (17.6%), and others (10.6%). The mean age onset of psoriasis for our study population was 35.14 ± 16.16 years. Male to female ratio was 1.3 : 1. 23.1% of patients had positive family history of psoriasis. The most common clinical presentation was chronic plaque psoriasis (85.1%), followed by guttate

2018 Dermatology research and practice

123. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. (Abstract)

Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. Assessment of disease severity is an essential component of psoriasis management. Moderate-to-severe disease qualifies for systemic treatment but different definitions are used.To analyse the impact of different severity definitions for psoriasis in real-world healthcare.Cross-sectional data on 3274 patients with psoriasis from more than 200 dermatology (...) offices and clinics across Germany were analysed for disease severity based on Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI). The proportions of patients having moderate-to-severe disease were determined accordingly.The proportion of patients meeting the European consensus criteria for moderate-to-severe psoriasis (PASI AND DLQI > 10) was 14·0%, although 45·3% attained at least PASI OR DLQI > 10. Consideration of all patients on systemic drugs as being 'moderate

2018 British Journal of Dermatology

124. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. (Abstract)

Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. 30387497 2019 02 04 1365-2133 180 2 2019 Feb The British journal of dermatology Br. J. Dermatol. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. 425-426 10.1111/bjd.17392 Li L L Shandong Provincial Hospital for Skin Diseases, Jinan

2018 British Journal of Dermatology

125. Mutational analysis of epidermal and hyperproliferative type I keratins in mild and moderate psoriasis vulgaris patients: a possible role in the pathogenesis of psoriasis along with disease severity Full Text available with Trip Pro

Mutational analysis of epidermal and hyperproliferative type I keratins in mild and moderate psoriasis vulgaris patients: a possible role in the pathogenesis of psoriasis along with disease severity Mutations in keratin proteins have been vastly associated with a wide array of genodermatoses; however, mutations of keratins in psoriasis have not been fully investigated. The main aim of the current research was to identify the mutation in K14, K10, K16, and K17 genes in two stages of psoriasis (...) and tolerated in nature. In these 33 deleterious mutations were immensely found to decrease keratin protein stability. We also found a correlation between keratin and Psoriasis Area and Severity Index score which added that alteration in keratin gene in skin causes severity of psoriasis.We strongly concluded that acanthosis and abnormal terminal differentiation was mainly due to the mutation in epidermal keratins. In turn, disease severity and relapsing of psoriasis are mainly due to the mutation

2018 Human Genomics

126. Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis Full Text available with Trip Pro

Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis 29852915 2018 11 14 1550-9397 14 6 2018 Jun 15 Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine J Clin Sleep Med Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis

2018 Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

127. Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study Full Text available with Trip Pro

Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study Generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) are the rare and severe subtypes of psoriasis, which are often difficult to treat. The aim of this phase 3, open-label study was to evaluate efficacy and safety of guselkumab, a human interleukin-23 (...) assessment of treatment-emergent adverse events (TEAE) through week 52. At week 16, the proportions of GPP and EP patients achieving treatment success were 77.8% (7/9) and 90.9% (10/11), respectively. Furthermore, guselkumab treatment consistently showed improvement in responses of secondary end-points such as Psoriasis Area and Severity Index, Investigator's Global Assessment, Japanese Dermatological Association severity index and improvement in body surface area involvement. Improvements in quality

2018 The Journal of dermatology

128. ‘Psoriasis 1’ reduces psoriasis-like skin inflammation by inhibiting the VDR-mediated nuclear NF-κB and STAT signaling pathways Full Text available with Trip Pro

‘Psoriasis 1’ reduces psoriasis-like skin inflammation by inhibiting the VDR-mediated nuclear NF-κB and STAT signaling pathways 'Psoriasis 1', a Chinese herbal medicine (CHM) formulation, is extensively used to treat psoriasis in China. Although this CHM formulation yields good therapeutic effect, the underlying mechanism of how this works remains unknown. The present study aimed to test the hypothesis that the CHM formulation 'psoriasis 1' inhibits vitamin D receptor (VDR)‑mediated (...) inflammation in psoriasis. To test this, a model of psoriasis was established by stimulating keratinocytes (HaCaT cells) with tumor necrosis factor (TNF)‑α; these cells were subsequently transfected with a lentiviral VDR RNA interference expression vector. The expression levels of 25‑hydroxyvitamin D3 (25HVD3), TNF‑α, interleukin (IL)‑4, IL‑1, IL‑17C, IL‑23 and IL‑6 were measured using ELISA, and the expression levels of VDR, inhibitor of nuclear factor (NF)‑κB (IKK), NF‑κB, signal transducer and activator

2018 Molecular medicine reports

129. Biological treatment for psoriasis and the risk of herpes zoster: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Full Text available with Trip Pro

Biological treatment for psoriasis and the risk of herpes zoster: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). To describe the risk of herpes zoster (HZ) in patients with psoriasis and its relation to non-biologic systemic therapies or biologic treatment.Psoriasis Longitudinal Assessment and Registry (PSOLAR) is an international, prospective, registry that follows adult patients with psoriasis eligible to receive non-biologic systemic therapies or biologic therapies

2018 Journal of Dermatological Treatment

130. Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab. (Abstract)

Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab. We sought to determine the psoriatic nail feature which responds to ustekinumab treatment more effectively, and evaluate which between the Nail Psoriasis Severity Index (NAPSI) and the Nijmegen-Nail psoriasis Activity Index tooL (N-NAIL) better reflects the clinical improvement of nail psoriasis.Thirty patients with moderate-to-severe plaque (...) psoriasis were prospectively enrolled and treated with ustekinumab for 52 weeks. A single investigator evaluated the condition using the NAPSI and the N-NAIL with serial fingernail photographs.Of the 30 patients, 13 (43.3%) had fingernail psoriasis present at baseline. Mean NAPSI scores improved from 9.46 ± 8.7 at baseline to 6.00 ± 5.2 at week 52, but the improvement was not statistically significant (p = .09). Mean N-NAIL scores significantly improved from 5.46 ± 5.1 at baseline to 3.92 ± 3.7 at week

2018 Journal of Dermatological Treatment

131. Patient Perceptions of Clear/Almost Clear Skin in Moderate-to-Severe Plaque Psoriasis: Results of the Clear About Psoriasis Worldwide Survey. Full Text available with Trip Pro

Patient Perceptions of Clear/Almost Clear Skin in Moderate-to-Severe Plaque Psoriasis: Results of the Clear About Psoriasis Worldwide Survey. Therapeutic advances have made the achievement of clear/almost clear skin possible for many patients with moderate-to-severe plaque psoriasis.To determine patient perceptions of the impact of psoriasis and of attaining clear/almost clear skin.Global survey of patients with moderate-to-severe psoriasis.A total of 8338 patients from 31 countries (...) participated. The majority (57%) had not achieved self-assessed clear/almost clear skin with their current therapy, and 56% of those who had not met this goal believed it would be impossible to do so. Among the patients who had clear/almost clear skin, 73% had not initiated their current treatment until >1 year after psoriasis diagnosis, and 28% had to wait >5 years. Eighty-four percent of all respondents experienced discrimination and/or humiliation due to psoriasis, and many reported negative effects

2018 Journal of the European Academy of Dermatology and Venereology

132. Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Full Text available with Trip Pro

Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). 29747219 2018 10 15 1365-2133 179 4 2018 Oct The British journal of dermatology Br. J. Dermatol. Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). 984-986 10.1111/bjd.16737 Kimball A B AB Harvard Medical

2018 British Journal of Dermatology

133. Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT). (Abstract)

Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT). Data on chronic plaque psoriasis severity and its potential clinical and lifestyle implications in the Brazilian population are limited. The primary aim of this study was to assess the clinical severity of plaque psoriasis in Brazil. Further objectives included evaluating potential associations between disease (...) severity and demographic, lifestyle, and clinical characteristics, health-related quality of life (HRQOL), and work productivity.This observational (non-interventional) cross-sectional study was conducted in 26 dermatologic clinics across 11 Brazilian states. Psoriasis severity was assessed using investigator judgment and Finlay's Rule of Tens: a Psoriasis Area and Severity Index (PASI) score >10, a Body Surface Area (BSA) > 10%, or a Dermatology Life Quality Index (DLQI) score >10.Among 1125 patients

2018 Journal of Dermatological Treatment

134. Author Correction to: Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. Full Text available with Trip Pro

Author Correction to: Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. In the original publication, section 5, paragraph 1 was incorrectly published.

2018 American journal of clinical dermatology

135. Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. (Abstract)

Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. 30102795 2019 02 12 1468-3083 33 2 2019 Feb Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. e74-e76 10.1111/jdv.15213 Kouwenhoven T A TA Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands. Bronckers I M G J IMGJ Department

2018 Journal of the European Academy of Dermatology and Venereology

136. Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Full Text available with Trip Pro

Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Optimal clinical management of psoriasis and psoriatic arthritis (PsA) Optimal clinical management of psoriasis and psoriatic arthritis (PsA) requires understanding of the impact on patients. The NORdic PAtient survey of Psoriasis and PsA (NORPAPP) aimed to obtain current data on disease prevalence (...) and patient perceptions in Sweden, Denmark and Norway. Among 22,050 individuals questioned, the reported prevalence of psoriasis and/or PsA was 9.7% (5.7% physician-diagnosed plus 4.0% self-diagnosed only); prevalence was similar in Sweden (9.4%) and Denmark (9.2%) but significantly higher in Norway (11.9%). Of those reporting a physician's diagnosis, 74.6% reported psoriasis alone, 10.3% PsA alone and 15.1% both. Patients with PsA perceived their disease to be more severe than those with psoriasis

2018 Acta Dermato-Venereologica

137. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. Full Text available with Trip Pro

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. We evaluated baseline itch and its impact on the efficacy of ixekizumab (IXE) in clearing psoriasis and improving quality-of-life measures, and we explored the relationship between itch and psoriatic skin improvement.Data were analyzed from two double-blind, randomized, controlled phase III studies (UNCOVER (...) -2/3) comparing etanercept (ETN), IXE, and placebo (PBO) in patients with moderate-to-severe plaque psoriasis. Long-term analysis included UNCOVER-3 data from week 0 to week 156.At week 12, a clinically meaningful improvement in itch [Itch Numeric Rating Scale (NRS) reduction ≥ 4] was seen in 70.0%, 88.6%, and 90.8% of the IXE-treated patients in the baseline Itch NRS 4-6, 7-8, and 9-10 groups, respectively (all itch severity groups p < 0.001 versus ETN and PBO). Also, 68.9%, 67.1%, and 73.6

2018 Dermatology and therapy Controlled trial quality: uncertain

138. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. Full Text available with Trip Pro

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. Health-related quality of life (HRQoL) may be markedly impaired in patients with moderate-to-severe psoriasis.Our objectives were to compare improvements in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) scores between patients (...) and signs score = 0, DLQI association with PSSD, Investigator's Global Assessment (IGA), and Psoriasis Area and Severity Index (PASI).Significantly greater improvements from baseline DLQI were observed with guselkumab versus placebo (weeks 8 and 16) and versus adalimumab (week 24; p < 0.001). The proportion of patients achieving DLQI 0/1 ("no impact") at week 24 was higher with guselkumab than with adalimumab (58.9 vs. 40.2%; p < 0.001), and more patients attained a ≥ 4-point reduction in DLQI (MCID

2018 American journal of clinical dermatology Controlled trial quality: uncertain

139. Apremilast for treating moderate to severe plaque psoriasis

Apremilast for treating moderate to severe plaque psoriasis Apremilast for treating moderate to severe plaque psoriasis | Guidance | NICE Apremilast for treating moderate to severe plaque psoriasis Technology appraisal guidance [TA368] Published date: 25 November 2015 Guidance . Explore © NICE [year]. All rights reserved. Subject to .

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

140. Secukinumab for treating moderate to severe plaque psoriasis

Secukinumab for treating moderate to severe plaque psoriasis Secukinumab for treating moder Secukinumab for treating moderate to ate to se sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta350 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psoriasis (plaque, moderate to severe) - secukinumab (TA350) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 50Contents Contents 1 Guidance 4 2 The technology 5 3 The company's

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>